Isracann Biosciences Inc.

IPOT

CA46501D1087

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 10:41:13 2023-04-05 am EDT			5-day change	1st Jan Change
0.015 ^CAD	-.--%		-.--%	-.--%

Jan. 23	Isracann Biosciences Inc. Announces Management Changes	CI
Jan. 23	Isracann Biosciences Inc. Announces Resignation of Yana Popova as CFO	CI

Isracann Biosciences Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022

December 07, 2022

Isracann Biosciences Inc. reported earnings results for the first quarter ended August 31, 2022. For the first quarter, the company reported net loss was CAD 0.315995 million compared to CAD 0.468842 million a year ago. Basic loss per share from continuing operations was CAD 0.002 compared to CAD 0.003 a year ago.

Latest news about Isracann Biosciences Inc.

Isracann Biosciences Inc. Announces Management Changes	Jan. 22	CI
Isracann Biosciences Inc. Announces Resignation of Yana Popova as CFO	Jan. 22	CI
Isracann Biosciences Inc. announced that it has received CAD 0.025 million in funding	23-02-15	CI
Isracann Biosciences Inc. Appoints Ajay Singh Kaila as Interim CEO	23-01-22	CI
Isracann Biosciences Inc. Announces Resignation of Phil Floucault as Chief Executive Officer	23-01-17	CI
Isracann Biosciences Inc. Announces Resignation of Phil Floucault as Director	23-01-17	CI
Isracann Biosciences Inc. Announces Resignation of James Thompson as Chief Operations Officer	23-01-16	CI
Isracann Biosciences Inc. Announces the Resignation of Irit Arbel as Director	22-12-20	CI
Isracann Biosciences Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022	22-12-07	CI
Isracann Biosciences Inc. Auditor Raises 'Going Concern' Doubt	22-11-29	CI
Isracann Biosciences Inc. Reports Earnings Results for the Full Year Ended May 31, 2022	22-11-29	CI
Isracann Bioscience Inc. Announces Facilitated Genetics Arrive in Israel	22-09-28	CI
Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel	22-09-14	CI
Isracann Inks Distribution Agreement with Pure Integrative Pharmacy for Praesidio Health Products	22-09-01	MT
Isracann Biosciences Inc. Signs Distribution Agreement with Pure Integrative Pharmacy	22-09-01	CI
Isracann Biosciences Inc. Appoints Mark Rypien to Its Advisory Board	22-08-23	CI
Isracann Biosciences Completes First Tranche of Private Placement	22-08-03	MT
Isracann Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	22-04-27	CI
Isracann Biosciences Inc. Announces Executive Changes	22-04-20	CI
Isracann Biosciences Renews Leadership, Announces $3 Million Financing	22-04-18	MT
Isracann Biosciences Inc. Announces Executive Changes	22-04-15	CI
Isracann Biosciences Inc. announced that it expects to receive CAD 2.940794 million in funding	22-04-14	CI
Isracann Biosciences Inc. Appoints George Vrabec to the Position of Director of Natural Health Products	22-04-13	CI
Isracann Biosciences Inc. completed the acquisition of Praesidio Health Inc.	22-04-11	CI
Isracann Biosciences Inc. entered into a binding Letter of Intent to acquire Praesidio Health Inc. for CAD 4 million.	22-02-22	CI

Chart Isracann Biosciences Inc.

Duration

Period

More charts

Company Profile

Isracann Biosciences Inc. is a Canada-based cannabis company. The principal business focus of the Company is medical cannabis cultivation and distribution to provide products to the Israeli medical cannabis market, and to develop and validate Natural Health Products (NHP), through the Companyâs operating subsidiaries. The Company's segments include Head Office, Medical Cannabis and Natural Health Product. The Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. The Company's subsidiaries include Isracann Holdings Inc., Praesidio Health Inc., Isracann Biosciences Capital Ltd., Isracann Operations Ltd., Isracann Development Ltd., Isracann Agritech Ltd., Isracann Administrative Services Ltd. and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ISRACANN BIOSCIENCES INC.	-.--%	1.94M
DONG-E-E-JIAO CO.,LTD.	+37.08%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-17.43%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.46%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+0.51%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.53%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.15%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-5.15%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.38%	1.53B